enalapril Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
angiotensin-converting enzyme inhibitors 1005 75847-73-3

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • enalapril
  • enalapril maleate
  • enarenal
Enalapril, after hydrolysis to enalaprilat, inhibits angiotensin-converting enzyme (ACE) in human subjects and animals. ACE is a peptidyl dipeptidase that catalyzes the conversion of angiotensin I to the vasoconstrictor substance, angiotensin II. Angiotensin II also stimulates aldosterone secretion by the adrenal cortex. Inhibition of ACE results in decreased plasma angiotensin II, which leads to decreased vasopressor activity and to decreased aldosterone secretion.
  • Molecular weight: 376.45
  • Formula: C20H28N2O5
  • CLOGP: 0.67
  • LIPINSKI: 0
  • HAC: 7
  • HDO: 2
  • TPSA: 95.94
  • ALOGS: -3.25
  • ROTB: 10

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
10 mg O
10 mg P

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 25 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 10 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 1.77 ┬ÁM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 63.50 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H

Approvals:

DateAgencyCompanyOrphan
Dec. 24, 1985 FDA VALEANT PHARMS NORTH

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Hyperkalaemia 1136.64 34.11 239 2083 5654 2350109
Acute kidney injury 1128.15 34.11 321 2001 27801 2327962
Hyponatraemia 573.62 34.11 162 2160 13163 2342600
Drug interaction 553.15 34.11 189 2133 28974 2326789
Hypotension 541.16 34.11 191 2131 32245 2323518
Angioedema 524.29 34.11 137 2185 8259 2347504
Lactic acidosis 312.81 34.11 83 2239 5247 2350516
Blood creatinine increased 220.61 34.11 74 2248 10459 2345304
Blood pressure increased 200.20 34.11 78 2244 16908 2338855
Diarrhoea 189.12 34.11 125 2197 83439 2272324
Bradycardia 188.82 34.11 65 2257 9916 2345847
Drug hypersensitivity 184.20 34.11 100 2222 46543 2309220
Renal failure 181.10 34.11 73 2249 17276 2338487
Vomiting 166.34 34.11 109 2213 71493 2284270
Dehydration 160.24 34.11 72 2250 22223 2333540
Toxicity to various agents 159.80 34.11 81 2241 32673 2323090
Hypertension 158.25 34.11 76 2246 27285 2328478
Hypoglycaemia 156.01 34.11 54 2268 8353 2347410
Coma 148.28 34.11 53 2269 9003 2346760
Dyspnoea 145.21 34.11 104 2218 78629 2277134
Cough 144.50 34.11 76 2246 33041 2322722
Toxic epidermal necrolysis 142.37 34.11 40 2282 3104 2352659
Inappropriate antidiuretic hormone secretion 135.35 34.11 36 2286 2273 2353490
Renal impairment 124.54 34.11 48 2274 10044 2345719
Syncope 122.70 34.11 55 2267 16820 2338943
Metabolic acidosis 120.84 34.11 41 2281 5957 2349806
Nausea 120.67 34.11 108 2214 112081 2243682
Swollen tongue 117.44 34.11 39 2283 5304 2350459
Dialysis 109.22 34.11 30 2292 2137 2353626
Dizziness 109.00 34.11 78 2244 58587 2297176
Orthostatic hypotension 100.80 34.11 30 2292 2849 2352914
Cardiac arrest 100.06 34.11 46 2276 14884 2340879
Drug ineffective 99.63 34.11 93 2229 101531 2254232
Tachycardia 98.97 34.11 47 2275 16362 2339401
Condition aggravated 97.31 34.11 58 2264 31921 2323842
Fall 95.22 34.11 66 2256 47033 2308730
Hypokalaemia 94.56 34.11 40 2282 10614 2345149
Cardiac failure 92.90 34.11 41 2281 12053 2343710
Blood pressure inadequately controlled 92.48 34.11 22 2300 878 2354885
Medication error 89.49 34.11 33 2289 6098 2349665
Completed suicide 85.11 34.11 46 2276 20988 2334775
Overdose 84.65 34.11 45 2277 19862 2335901
Confusional state 84.17 34.11 48 2274 24296 2331467
Blood pressure decreased 83.02 34.11 35 2287 9201 2346562
Acidosis 79.78 34.11 22 2300 1588 2354175
Blood glucose increased 79.60 34.11 37 2285 12253 2343510
Electrocardiogram QRS complex prolonged 78.14 34.11 20 2302 1082 2354681
General physical health deterioration 77.65 34.11 38 2284 14101 2341662
Malaise 76.76 34.11 62 2260 55523 2300240
Blood urea increased 73.95 34.11 25 2297 3580 2352183
Oedema peripheral 71.93 34.11 43 2279 23720 2332043
Hypertensive crisis 70.10 34.11 22 2300 2491 2353272
Haemodialysis 69.97 34.11 21 2301 2048 2353715
Atrioventricular block complete 68.57 34.11 19 2303 1395 2354368
Intentional overdose 66.89 34.11 32 2290 11289 2344474
Haemoglobin decreased 65.95 34.11 37 2285 18114 2337649
Sinus bradycardia 65.23 34.11 20 2302 2096 2353667
Asthenia 61.89 34.11 51 2271 46875 2308888
Presyncope 61.16 34.11 22 2300 3781 2351982
Glycosylated haemoglobin increased 59.37 34.11 18 2304 1816 2353947
Hepatic steatosis 57.03 34.11 20 2302 3193 2352570
Loss of consciousness 56.86 34.11 34 2288 18733 2337030
Depressed level of consciousness 55.83 34.11 25 2297 7579 2348184
Atrial fibrillation 55.31 34.11 30 2292 13738 2342025
Hypovolaemic shock 53.94 34.11 14 2308 800 2354963
Headache 53.82 34.11 60 2262 80119 2275644
Loss of employment 52.70 34.11 10 2312 130 2355633
Proteinuria 51.57 34.11 18 2304 2832 2352931
Tubulointerstitial nephritis 50.35 34.11 17 2305 2421 2353342
Dysphonia 50.18 34.11 22 2300 6342 2349421
Exposure during pregnancy 50.00 34.11 35 2287 25184 2330579
Somnolence 49.86 34.11 34 2288 23451 2332312
Dysphagia 48.93 34.11 27 2295 12778 2342985
Decreased appetite 47.95 34.11 36 2286 28855 2326908
Tachypnoea 47.84 34.11 16 2306 2213 2353550
Pneumonia 47.76 34.11 45 2277 49251 2306512
Hypertensive heart disease 46.86 34.11 11 2311 413 2355350
Intestinal angioedema 46.74 34.11 9 2313 127 2355636
Blood sodium decreased 46.36 34.11 17 2305 3083 2352680
Klebsiella infection 44.35 34.11 12 2310 805 2354958
Serotonin syndrome 44.16 34.11 17 2305 3523 2352240
Blood potassium increased 44.12 34.11 15 2307 2181 2353582
Tongue oedema 43.88 34.11 12 2310 838 2354925
Pancreatitis acute 42.76 34.11 17 2305 3836 2351927
Rash 42.37 34.11 46 2276 59512 2296251
Alanine aminotransferase increased 41.38 34.11 25 2297 14007 2341756
Hypoxia 41.05 34.11 19 2303 6208 2349555
C-reactive protein increased 40.97 34.11 19 2303 6236 2349527
Haematocrit decreased 40.89 34.11 17 2305 4301 2351462
Cardiac failure congestive 40.68 34.11 26 2296 16075 2339688
Blood pressure systolic decreased 40.56 34.11 11 2311 744 2355019
Abdominal pain 40.39 34.11 35 2287 34339 2321424
Electrocardiogram P wave abnormal 40.08 34.11 7 2315 55 2355708
Blood bicarbonate decreased 39.95 34.11 10 2312 493 2355270
Hypovolaemia 39.76 34.11 12 2310 1191 2354572
Cerebellar syndrome 38.52 34.11 10 2312 571 2355192
Chronic kidney disease 38.27 34.11 16 2306 4102 2351661
Hyponatraemic encephalopathy 38.13 34.11 7 2315 75 2355688
Atrioventricular block first degree 37.87 34.11 11 2311 956 2354807
Muscular weakness 37.50 34.11 24 2298 14873 2340890
Hypertrichosis 36.52 34.11 8 2314 219 2355544
Pancreatitis 36.35 34.11 19 2303 8060 2347703
Gastroenteritis 35.70 34.11 14 2308 3046 2352717
Arrhythmia 35.45 34.11 17 2305 6011 2349752
Renal failure neonatal 34.72 34.11 6 2316 44 2355719
Stevens-Johnson syndrome 34.46 34.11 15 2307 4244 2351519
Erythema 34.45 34.11 28 2294 25131 2330632
Electrocardiogram abnormal 34.26 34.11 11 2311 1337 2354426

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Acute kidney injury 1030.87 39.70 363 2178 34581 1709659
Angioedema 844.14 39.70 232 2309 9432 1734808
Hyperkalaemia 693.60 39.70 194 2347 8353 1735887
Hypotension 450.36 39.70 192 2349 29462 1714778
Drug interaction 400.90 39.70 174 2367 27784 1716456
Cardiac failure 277.33 39.70 107 2434 12495 1731745
Syncope 265.16 39.70 107 2434 14062 1730178
Dehydration 229.52 39.70 103 2438 17555 1726685
Blood creatinine increased 219.04 39.70 93 2448 13853 1730387
Blood pressure decreased 197.07 39.70 73 2468 7573 1736667
Dyspnoea 159.22 39.70 118 2423 51941 1692299
Hyponatraemia 144.26 39.70 61 2480 8939 1735301
Renal failure 138.01 39.70 76 2465 19941 1724299
Completed suicide 129.36 39.70 68 2473 16244 1727996
Renal impairment 122.91 39.70 60 2481 12254 1731986
Dizziness 120.92 39.70 85 2456 34276 1709964
Concomitant disease progression 111.88 39.70 26 2515 506 1743734
Swollen tongue 111.29 39.70 37 2504 2771 1741469
Bradycardia 110.12 39.70 53 2488 10481 1733759
Fall 106.66 39.70 72 2469 27142 1717098
Toxicity to various agents 99.87 39.70 71 2470 29070 1715170
Chest pain 93.38 39.70 59 2482 19855 1724385
Cough 92.83 39.70 58 2483 19139 1725101
Ventricular tachycardia 89.40 39.70 34 2507 3764 1740476
Hypertension 87.14 39.70 56 2485 19392 1724848
Cardiac arrest 86.89 39.70 52 2489 15878 1728362
Atrial fibrillation 86.79 39.70 51 2490 15060 1729180
Condition aggravated 85.26 39.70 57 2484 21093 1723147
Lactic acidosis 82.83 39.70 35 2506 5094 1739146
Blood pressure increased 82.74 39.70 44 2497 10709 1733531
Pharyngeal oedema 82.68 39.70 26 2515 1627 1742613
Drug ineffective 82.31 39.70 89 2452 63712 1680528
Cardiac failure chronic 81.77 39.70 21 2520 627 1743613
Vertigo 81.01 39.70 33 2508 4380 1739860
Blood urea increased 78.92 39.70 33 2508 4678 1739562
Chronic kidney disease 78.27 39.70 32 2509 4285 1739955
Hypoglycaemia 77.79 39.70 39 2502 8399 1735841
Speech disorder 76.66 39.70 32 2509 4516 1739724
Vomiting 76.56 39.70 68 2473 38247 1705993
Hypokalaemia 75.53 39.70 35 2506 6339 1737901
Inappropriate antidiuretic hormone secretion 73.10 39.70 24 2517 1724 1742516
Blood potassium increased 71.82 39.70 26 2515 2504 1741736
Orthostatic hypotension 67.58 39.70 27 2514 3404 1740836
Atrioventricular block complete 64.76 39.70 21 2520 1450 1742790
Swelling face 63.84 39.70 28 2513 4455 1739785
Anuria 63.46 39.70 22 2519 1866 1742374
Drug hypersensitivity 61.41 39.70 41 2500 15094 1729146
Diarrhoea 60.50 39.70 70 2471 53782 1690458
Nausea 58.25 39.70 67 2474 51129 1693111
Pancreatitis acute 56.49 39.70 25 2516 4062 1740178
Arrhythmia 55.98 39.70 28 2513 5988 1738252
General physical health deterioration 54.32 39.70 36 2505 13082 1731158
Supernumerary nipple 54.03 39.70 8 2533 6 1744234
Loss of consciousness 52.53 39.70 37 2504 14838 1729402
Presyncope 52.32 39.70 21 2520 2677 1741563
Febrile neutropenia 52.19 39.70 33 2508 11067 1733173
Carotid sinus syndrome 51.18 39.70 8 2533 12 1744228
Oedema peripheral 51.05 39.70 37 2504 15513 1728727
Product complaint 50.43 39.70 20 2521 2470 1741770
Tongue oedema 49.62 39.70 14 2527 600 1743640
Acidosis 48.59 39.70 17 2524 1480 1742760
Congenital hearing disorder 47.94 39.70 8 2533 22 1744218
Rales 47.69 39.70 15 2526 937 1743303
Bundle branch block right 47.42 39.70 16 2525 1249 1742991
Asthenia 47.36 39.70 50 2491 34620 1709620
Malaise 46.47 39.70 46 2495 29519 1714721
Respiratory failure 46.44 39.70 34 2507 14471 1729769
Haemodialysis 46.05 39.70 19 2522 2597 1741643
Anaemia 44.76 39.70 45 2496 29412 1714828
Dysphagia 44.74 39.70 29 2512 10139 1734101
Leukocytosis 43.69 39.70 20 2521 3513 1740727
Kidney duplex 43.54 39.70 8 2533 44 1744196
Overdose 42.18 39.70 34 2507 16667 1727573
Haemoglobin decreased 41.45 39.70 34 2507 17080 1727160
Gingival hypertrophy 41.38 39.70 11 2530 376 1743864
Metabolic acidosis 41.19 39.70 22 2519 5380 1738860
Cardiogenic shock 40.42 39.70 17 2524 2437 1741803
Cardiac failure acute 40.28 39.70 14 2527 1195 1743045

Pharmacologic Action:

SourceCodeDescription
ATC C09AA02 CARDIOVASCULAR SYSTEM
AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM
ACE INHIBITORS, PLAIN
ACE inhibitors, plain
ATC C09BA02 CARDIOVASCULAR SYSTEM
AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM
ACE INHIBITORS, COMBINATIONS
ACE inhibitors and diuretics
ATC C09BB02 CARDIOVASCULAR SYSTEM
AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM
ACE INHIBITORS, COMBINATIONS
ACE inhibitors and calcium channel blockers
ATC C09BB06 CARDIOVASCULAR SYSTEM
AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM
ACE INHIBITORS, COMBINATIONS
ACE inhibitors and calcium channel blockers
FDA EPC N0000175562 Angiotensin Converting Enzyme Inhibitor
FDA PE N0000178477 Decreased Blood Pressure
MeSH PA D000806 Angiotensin-Converting Enzyme Inhibitors
MeSH PA D000959 Antihypertensive Agents
MeSH PA D002317 Cardiovascular Agents
MeSH PA D004791 Enzyme Inhibitors
MeSH PA D011480 Protease Inhibitors
CHEBI has role CHEBI:50266 prodrug
CHEBI has role CHEBI:35457 EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor
CHEBI has role CHEBI:35674 antihypertensive agent

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Hypertensive disorder indication 38341003 DOID:10763
Congestive heart failure indication 42343007 DOID:6000
Asymptomatic left ventricular systolic dysfunction indication 698592004
Angioedema contraindication 41291007 DOID:1558
Hereditary angioneurotic edema contraindication 82966003 DOID:14735
Idiopathic angioedema contraindication 402382008

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 3.14 acidic
pKa2 5.91 Basic

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
1MG/ML EPANED KIT SILVERGATE PHARMS N204308 Aug. 13, 2013 DISCN FOR SOLUTION ORAL 8778366 Nov. 6, 2032 METHOD OF TREATING HYPERTENSION
1MG/ML EPANED KIT SILVERGATE PHARMS N204308 Aug. 13, 2013 DISCN FOR SOLUTION ORAL 8778366 Nov. 6, 2032 METHOD OF TREATING LEFT VENTRICULAR DYSFUNCTION
1MG/ML EPANED KIT SILVERGATE PHARMS N204308 Aug. 13, 2013 DISCN FOR SOLUTION ORAL 8778366 Nov. 6, 2032 METHOD OF TREATMENT OF HEART FAILURE
1MG/ML EPANED KIT SILVERGATE PHARMS N204308 Aug. 13, 2013 DISCN FOR SOLUTION ORAL 8778366 Nov. 6, 2032 TREATMENT OF HEART FAILURE
1MG/ML EPANED KIT SILVERGATE PHARMS N204308 Aug. 13, 2013 DISCN FOR SOLUTION ORAL 8778366 Nov. 6, 2032 TREATMENT OF HYPERTENSION
1MG/ML EPANED KIT SILVERGATE PHARMS N204308 Aug. 13, 2013 DISCN FOR SOLUTION ORAL 9968553 Nov. 6, 2032 METHOD OF TREATING HYPERTENSION
1MG/ML EPANED KIT SILVERGATE PHARMS N204308 Aug. 13, 2013 DISCN FOR SOLUTION ORAL 9968553 Nov. 6, 2032 METHOD OF TREATING LEFT VENTRICULAR DYSFUNCTION
1MG/ML EPANED KIT SILVERGATE PHARMS N204308 Aug. 13, 2013 DISCN FOR SOLUTION ORAL 9968553 Nov. 6, 2032 METHOD OF TREATMENT OF HEART FAILURE
1MG/ML EPANED KIT SILVERGATE PHARMS N204308 Aug. 13, 2013 DISCN FOR SOLUTION ORAL 9968553 Nov. 6, 2032 TREATMENT OF HEART FAILURE
1MG/ML EPANED KIT SILVERGATE PHARMS N204308 Aug. 13, 2013 DISCN FOR SOLUTION ORAL 9968553 Nov. 6, 2032 TREATMENT OF HYPERTENSION
1MG/ML EPANED SILVERGATE PHARMS N208686 Sept. 20, 2016 RX SOLUTION ORAL 10154987 March 25, 2036 METHOD OF TREATING HYPERTENSION
1MG/ML EPANED SILVERGATE PHARMS N208686 Sept. 20, 2016 RX SOLUTION ORAL 10154987 March 25, 2036 METHOD OF TREATING LEFT VENTRICULAR DYSFUNCTION
1MG/ML EPANED SILVERGATE PHARMS N208686 Sept. 20, 2016 RX SOLUTION ORAL 10154987 March 25, 2036 METHOD OF TREATMENT OF HEART FAILURE
1MG/ML EPANED SILVERGATE PHARMS N208686 Sept. 20, 2016 RX SOLUTION ORAL 10154987 March 25, 2036 TREATMENT OF HEART FAILURE
1MG/ML EPANED SILVERGATE PHARMS N208686 Sept. 20, 2016 RX SOLUTION ORAL 10154987 March 25, 2036 TREATMENT OF HYPERTENSION
1MG/ML EPANED SILVERGATE PHARMS N208686 Sept. 20, 2016 RX SOLUTION ORAL 9808442 March 25, 2036 METHOD OF TREATING HYPERTENSION
1MG/ML EPANED SILVERGATE PHARMS N208686 Sept. 20, 2016 RX SOLUTION ORAL 9808442 March 25, 2036 METHOD OF TREATING LEFT VENTRICULAR DYSFUNCTION
1MG/ML EPANED SILVERGATE PHARMS N208686 Sept. 20, 2016 RX SOLUTION ORAL 9808442 March 25, 2036 METHOD OF TREATMENT OF HEART FAILURE
1MG/ML EPANED SILVERGATE PHARMS N208686 Sept. 20, 2016 RX SOLUTION ORAL 9808442 March 25, 2036 TREATMENT OF HEART FAILURE
1MG/ML EPANED SILVERGATE PHARMS N208686 Sept. 20, 2016 RX SOLUTION ORAL 9808442 March 25, 2036 TREATMENT OF HYPERTENSION

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Angiotensin-converting enzyme Enzyme INHIBITOR IC50 4.30 IUPHAR IUPHAR
Angiotensin-converting enzyme Enzyme IC50 6.10 CHEMBL
Angiotensin-converting enzyme Enzyme IC50 6.85 CHEMBL

External reference:

IDSource
D004656 MESH_DESCRIPTOR_UI
4019744 VUID
N0000147835 NUI
C0014025 UMLSCUI
D00621 KEGG_DRUG
69PN84IO1A UNII
5117 INN_ID
15222008 SNOMEDCT_US
3827 RXNORM
372658000 SNOMEDCT_US
4655 MMSL
d00013 MMSL
4019744 VANDF
004500 NDDF
76095-16-4 SECONDARY_CAS_RN
CHEMBL578 ChEMBL_ID
DB00584 DRUGBANK_ID
CHEMBL1200659 ChEMBL_ID
CHEBI:4784 CHEBI
6322 IUPHAR_LIGAND_ID
5388962 PUBCHEM_CID
DB09477 DRUGBANK_ID

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Enalapril Maleate HUMAN PRESCRIPTION DRUG LABEL 1 0093-0026 TABLET 2.50 mg ORAL ANDA 12 sections
Enalapril Maleate HUMAN PRESCRIPTION DRUG LABEL 1 0093-0027 TABLET 5 mg ORAL ANDA 12 sections
Enalapril Maleate HUMAN PRESCRIPTION DRUG LABEL 1 0093-0028 TABLET 10 mg ORAL ANDA 12 sections
Enalapril Maleate HUMAN PRESCRIPTION DRUG LABEL 1 0093-0029 TABLET 20 mg ORAL ANDA 12 sections
Vasotec HUMAN PRESCRIPTION DRUG LABEL 1 0187-0140 TABLET 2.50 mg ORAL NDA 13 sections
Vasotec HUMAN PRESCRIPTION DRUG LABEL 1 0187-0141 TABLET 5 mg ORAL NDA 13 sections
Vasotec HUMAN PRESCRIPTION DRUG LABEL 1 0187-0142 TABLET 10 mg ORAL NDA 13 sections
Vasotec HUMAN PRESCRIPTION DRUG LABEL 1 0187-0143 TABLET 20 mg ORAL NDA 13 sections
Vaseretic HUMAN PRESCRIPTION DRUG LABEL 2 0187-0146 TABLET 10 mg ORAL NDA 13 sections
Enalapril Maleate and Hydrochlorothiazide HUMAN PRESCRIPTION DRUG LABEL 2 0378-0712 TABLET 5 mg ORAL ANDA 12 sections
Enalapril Maleate and Hydrochlorothiazide HUMAN PRESCRIPTION DRUG LABEL 2 0378-0723 TABLET 10 mg ORAL ANDA 12 sections
ENALAPRIL MALEATE HUMAN PRESCRIPTION DRUG LABEL 1 0615-4589 TABLET 2.50 mg ORAL ANDA 12 sections
ENALAPRIL MALEATE HUMAN PRESCRIPTION DRUG LABEL 1 0615-4590 TABLET 5 mg ORAL ANDA 12 sections
ENALAPRIL MALEATE HUMAN PRESCRIPTION DRUG LABEL 1 0615-4591 TABLET 10 mg ORAL ANDA 12 sections
ENALAPRIL MALEATE HUMAN PRESCRIPTION DRUG LABEL 1 0615-4593 TABLET 20 mg ORAL ANDA 12 sections
Enalapril Maleate and Hydrochlorothiazide HUMAN PRESCRIPTION DRUG LABEL 2 0713-1044 TABLET 5 mg ORAL ANDA 12 sections
Enalapril Maleate and Hydrochlorothiazide HUMAN PRESCRIPTION DRUG LABEL 2 0713-1052 TABLET 10 mg ORAL ANDA 12 sections
Enalapril Maleate HUMAN PRESCRIPTION DRUG LABEL 1 0781-5441 TABLET 2.50 mg ORAL ANDA 12 sections
Enalapril Maleate HUMAN PRESCRIPTION DRUG LABEL 1 0781-5442 TABLET 5 mg ORAL ANDA 12 sections
Enalapril Maleate HUMAN PRESCRIPTION DRUG LABEL 1 0781-5443 TABLET 10 mg ORAL ANDA 12 sections
Enalapril Maleate HUMAN PRESCRIPTION DRUG LABEL 1 0781-5444 TABLET 20 mg ORAL ANDA 12 sections
ENALAPRIL MALEATE HUMAN PRESCRIPTION DRUG LABEL 1 0904-5502 TABLET 5 mg ORAL ANDA 13 sections
ENALAPRIL MALEATE HUMAN PRESCRIPTION DRUG LABEL 1 0904-5609 TABLET 2.50 mg ORAL ANDA 13 sections
ENALAPRIL MALEATE HUMAN PRESCRIPTION DRUG LABEL 1 0904-5610 TABLET 10 mg ORAL ANDA 13 sections
ENALAPRIL MALEATE HUMAN PRESCRIPTION DRUG LABEL 1 0904-5611 TABLET 20 mg ORAL ANDA 13 sections
ENALAPRIL MALEATE HUMAN PRESCRIPTION DRUG LABEL 1 10544-170 TABLET 10 mg ORAL ANDA 13 sections
Enalapril Maleate HUMAN PRESCRIPTION DRUG LABEL 1 10544-195 TABLET 10 mg ORAL ANDA 13 sections
Enalapril Maleate HUMAN PRESCRIPTION DRUG LABEL 1 10544-293 TABLET 5 mg ORAL ANDA 13 sections
Enalapril Maleate HUMAN PRESCRIPTION DRUG LABEL 1 10544-632 TABLET 10 mg ORAL ANDA 13 sections
Enalapril Maleate HUMAN PRESCRIPTION DRUG LABEL 1 10544-633 TABLET 20 mg ORAL ANDA 13 sections